|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-3-4
|
|
pubmed:abstractText |
Rituximab is used after kidney transplant to prevention or treat kidney-allograft rejection. However, the impact of rituximab on the ability of patients to respond to tetanus toxoid vaccination has not yet been studied.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1304-0855
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
19-28
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20199367-Adult,
pubmed-meshheading:20199367-Aged,
pubmed-meshheading:20199367-Antibodies, Monoclonal,
pubmed-meshheading:20199367-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20199367-B-Lymphocytes,
pubmed-meshheading:20199367-CD4-Positive T-Lymphocytes,
pubmed-meshheading:20199367-Cell Count,
pubmed-meshheading:20199367-Female,
pubmed-meshheading:20199367-Graft Rejection,
pubmed-meshheading:20199367-Humans,
pubmed-meshheading:20199367-Immunity, Humoral,
pubmed-meshheading:20199367-Immunoglobulins,
pubmed-meshheading:20199367-Immunosuppressive Agents,
pubmed-meshheading:20199367-Kidney Diseases,
pubmed-meshheading:20199367-Kidney Transplantation,
pubmed-meshheading:20199367-Male,
pubmed-meshheading:20199367-Middle Aged,
pubmed-meshheading:20199367-Tetanus Toxoid
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
|
|
pubmed:affiliation |
Laboratoire d'Immunologie, CHU de Toulouse, Hopital Rangueil, France.
|
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
